Aug 5 |
BioXcel Therapeutics Q2 2024 Earnings Preview
|
Jul 30 |
BioXcel Therapeutics to Report Second Quarter 2024 Financial Results on August 6, 2024
|
Jul 16 |
BioXcel Therapeutics expects 141% Y/Y revenue surge for Q2
|
Jul 16 |
BioXcel Therapeutics Announces Preliminary Estimated Unaudited Second Quarter Net Revenues from Sales of IGALMI™ (dexmedetomidine) Sublingual Film
|
Jun 25 |
BioXcel Therapeutics' Approved Drug For Bipolar Disorders/Schizophrenia Shows No Evidence Of Worsening Or Withdrawal In Post-Marketing Study
|
Jun 25 |
BioXcel Therapeutics Announces Positive Topline Results from Post-Marketing Requirement Study Evaluating PRN Treatment of IGALMI™ (dexmedetomidine) Sublingual Film for Agitation Associated with Bipolar Disorders or Schizophrenia
|
May 28 |
BioXcel Therapeutics to Present at Jefferies Global Healthcare Conference
|
May 21 |
BioXcel Therapeutics Announces Oral and Poster Presentations at the 2024 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting
|
May 10 |
BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q1 2024 Earnings Call Transcript
|
May 10 |
BioXcel Therapeutics First Quarter 2024 Earnings: Misses Expectations
|